FOLH1 and neoplasm: Radiopharmaceuticals conjugated with albumin binders, such as 4-(p-iodophenyl)butyric acid and truncated Evans Blue (EB), have been used in radiotherapy targeting folate receptor [5,6,7], somatostatin receptor (SSTR) [8,9], integrin αvβ3/αvβ5 [10] and prostate-specific membrane antigen (PSMA) [11,12,13,14] and have achieved significantly prolonged blood circulation, with enhanced tumor suppression [3,15].